Peter Larson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Peter Larson has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- David M. Ferguson
Department of Medicinal Chemistry, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA
3 shared publications - Jayanth Panyam
Department of Pharmaceutics, College of Pharmacy, University of Washington, Seattle, WA 98195, USA
2 shared publications - Thomas S. Griffith
Center for Immunology, University of Minnesota , Minneapolis, MN
2 shared publications - Cara Skon-Hegg
University of Minnesota
1 shared publication - Daohai Yu
Center for Biostatistics & Epidemiology, Department of Biomedical Education and Data Science, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA
1 shared publication - John Schultz
University of Minnesota
1 shared publication
Latest Publications
- Open Access
- 3 November 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Discovery of Highly Potent C7 Methyl Acetate Substituted Imidazoquinoline-Based TLR7 and TLR8 Agonists
A series of highly substituted imidazoquinolines were synthesized and evaluated for Toll-like receptor (TLR) 7 and 8 activity and potency in stimulating pro-inflammatory cytokine production. The approach applies structure activity relationship data to evaluate the potentiating effects of ring substitutions to the C7-position. Our results show a clear correlation between the inclusion of a C7 methyl acetate group and TLR7 and 8 activity of substituted imidazoquinoline analogs. The most active compounds identified also contain C2 butyl and N1 aminobenzyl substitutions with several analogs displaying single digit nanomolar TLR7 agonist activity. The immunostimulatory effects of the compounds were further evaluated in vitro using human peripheral blood mononuclear cells (PBMCs) and mouse bone marrow-derived dendritic cells (BMDCs). The most potent compounds induce significant production of TNF-α, IL-1β, and IFN-γ by PBMC and expression of MHC II, CD40, and CD80 on BMDCs. A structural model of the TLR7-agonist complex is presented that shows the C7 acetate forms stabilizing H-bonding contacts with several charged amino acid sidechains near the surface of the receptor. The collective results provide strong evidence that correlates the enhanced potency of the C7 acetate analogs to recognition elements at this new site, providing insight to the design of TLR7 and TLR8 ligands.
- 3 November 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessDiscovery of Highly Potent C7 Methyl Acetate Substituted Imidazoquinoline-Based TLR7 and TLR8 Agonists
A series of highly substituted imidazoquinolines were synthesized and evaluated for Toll-like receptor (TLR) 7 and 8 activity and potency in stimulating pro-inflammatory cytokine production. The approach applies structure activity relationship data to evaluate the potentiating effects of ring substitutions to the C7-position. Our results show a clear correlation between the inclusion of a C7 methyl acetate group and TLR7 and 8 activity of substituted imidazoquinoline analogs. The most active compounds identified also contain C2 butyl and N1 aminobenzyl substitutions with several analogs displaying single digit nanomolar TLR7 agonist activity. The immunostimulatory effects of the compounds were further evaluated in vitro using human peripheral blood mononuclear cells (PBMCs) and mouse bone marrow-derived dendritic cells (BMDCs). The most potent compounds induce significant production of TNF-α, IL-1β, and IFN-γ by PBMC and expression of MHC II, CD40, and CD80 on BMDCs. A structural model of the TLR7-agonist complex is presented that shows the C7 acetate forms stabilizing H-bonding contacts with several charged amino acid sidechains near the surface of the receptor. The collective results provide strong evidence that correlates the enhanced potency of the C7 acetate analogs to recognition elements at this new site, providing insight to the design of TLR7 and TLR8 ligands.
- Open Access
Combination of STING and TLR 7/8 Agonists as Vaccine Adjuvants for Cancer Immunotherapy
Immunostimulatory adjuvants that potently activate antigen-presenting cells and (in turn) prime cytotoxic T cells are a key component of anticancer vaccines. In this study, we investigated a multi-adjuvant approach combining a TLR 7/8 agonist (522) and a STING agonist (DMXAA) to promote enhanced antigen cross-presentation, stimulate specific antitumor T-cell responses, and provide improved anticancer efficacy. In vitro experiments using bone marrow-derived dendritic cells (BMDCs) confirmed enhanced activation with the 522-DMXAA combination based on both co-stimulatory molecule expression and pro-inflammatory cytokine secretion. The immunization of mice with vaccines comprising both 522 and DMXAA resulted in greater antitumor efficacy in B16F10 melanoma and MB49 bladder tumor models relative to mono-agonist vaccines. Flow cytometry-based analysis of immune cells from immunized mice revealed the significant activation of antigen-presenting cells, increased numbers of activated and Ag-specific CD8+ T cells in the spleen and lymph nodes, modest NK cell activation, and an overall reduction in CD206+ macrophages. These results were supported by an increase in the levels of IFN-γ and a reduction in IL-10 levels in the sera. Taken together, these findings demonstrate the potential of the TLR7/8 and STING agonist combination as vaccine adjuvants to activate both innate and adaptive immune responses.
Open AccessCombination of STING and TLR 7/8 Agonists as Vaccine Adjuvants for Cancer Immunotherapy
Immunostimulatory adjuvants that potently activate antigen-presenting cells and (in turn) prime cytotoxic T cells are a key component of anticancer vaccines. In this study, we investigated a multi-adjuvant approach combining a TLR 7/8 agonist (522) and a STING agonist (DMXAA) to promote enhanced antigen cross-presentation, stimulate specific antitumor T-cell responses, and provide improved anticancer efficacy. In vitro experiments using bone marrow-derived dendritic cells (BMDCs) confirmed enhanced activation with the 522-DMXAA combination based on both co-stimulatory molecule expression and pro-inflammatory cytokine secretion. The immunization of mice with vaccines comprising both 522 and DMXAA resulted in greater antitumor efficacy in B16F10 melanoma and MB49 bladder tumor models relative to mono-agonist vaccines. Flow cytometry-based analysis of immune cells from immunized mice revealed the significant activation of antigen-presenting cells, increased numbers of activated and Ag-specific CD8+ T cells in the spleen and lymph nodes, modest NK cell activation, and an overall reduction in CD206+ macrophages. These results were supported by an increase in the levels of IFN-γ and a reduction in IL-10 levels in the sera. Taken together, these findings demonstrate the potential of the TLR7/8 and STING agonist combination as vaccine adjuvants to activate both innate and adaptive immune responses.
- Open Access
4-Amino-2-butyl-7-methoxycarbonylthiazolo[4,5-c]quinoline
4-Amino-imidazo-, oxazolo-, and thiazoloquinolines are key structural scaffolds in the design of nucleoside base analogs for use as therapeutic agents. Current strategies for arriving at diverse substitutions at the C6–C9 positions of the thiazolo- and oxazoloquinolines, however, are limited due to difficulties in arriving at the thiazoloquinoline-5N-oxide intermediate using electron deficient aromatic systems. Here, we demonstrate a synthetic route to obtain substituted thiazoloquinolines with electron-withdrawing groups at the C7 position. The target compound, 4-amino-2-butyl-7-methoxycarbonylthiazolo[4,5-c]quinoline, is obtained in eight steps using a 7-bromo surrogate as a precursor to the successful generation of the N-oxide intermediate, and final transformation via Pd-mediated C7-acylation.
Open Access4-Amino-2-butyl-7-methoxycarbonylthiazolo[4,5-c]quinoline
4-Amino-imidazo-, oxazolo-, and thiazoloquinolines are key structural scaffolds in the design of nucleoside base analogs for use as therapeutic agents. Current strategies for arriving at diverse substitutions at the C6–C9 positions of the thiazolo- and oxazoloquinolines, however, are limited due to difficulties in arriving at the thiazoloquinoline-5N-oxide intermediate using electron deficient aromatic systems. Here, we demonstrate a synthetic route to obtain substituted thiazoloquinolines with electron-withdrawing groups at the C7 position. The target compound, 4-amino-2-butyl-7-methoxycarbonylthiazolo[4,5-c]quinoline, is obtained in eight steps using a 7-bromo surrogate as a precursor to the successful generation of the N-oxide intermediate, and final transformation via Pd-mediated C7-acylation.